MA53973A - Inhibiteurs de la réplication du virus de l'immunodéficience humaine - Google Patents

Inhibiteurs de la réplication du virus de l'immunodéficience humaine

Info

Publication number: MA53973A
Authority: MA; Morocco
Prior art keywords: immunodeficiency virus; human immunodeficiency; virus replication; replication inhibitors; inhibitors
Prior art date: 2018-10-24

Application number

MA053973A

Other languages

English (en)

Inventor

Eric P Gillis

Kyle E Parcella

Manoj Patel

Kevin M Peese

Original Assignee

Viiv Healthcare Uk No 5 Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2018-10-24

Filing date

2019-10-22

Publication date

2022-02-09

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=68344933&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA53973(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2019-10-22 Application filed by Viiv Healthcare Uk No 5 Ltd filed Critical Viiv Healthcare Uk No 5 Ltd

2022-02-09 Publication of MA53973A publication Critical patent/MA53973A/fr

Links

241000725303 Human immunodeficiency virus Species 0.000 title 1
239000003112 inhibitor Substances 0.000 title 1
230000029812 viral genome replication Effects 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Organic Chemistry (AREA)
Molecular Biology (AREA)
Dermatology (AREA)
Nutrition Science (AREA)
Physiology (AREA)
Virology (AREA)
Oncology (AREA)
Tropical Medicine & Parasitology (AREA)
Communicable Diseases (AREA)
AIDS & HIV (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Plural Heterocyclic Compounds (AREA)

MA053973A 2018-10-24 2019-10-22 Inhibiteurs de la réplication du virus de l'immunodéficience humaine MA53973A (fr)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US201862749818P	2018-10-24	2018-10-24

Publications (1)

Publication Number	Publication Date
MA53973A true MA53973A (fr)	2022-02-09

Family

ID=68344933

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
MA053973A MA53973A (fr)	2018-10-24	2019-10-22	Inhibiteurs de la réplication du virus de l'immunodéficience humaine

Country Status (25)

Country	Link
US (2)	US11541055B2 (fr)
EP (1)	EP3870577B1 (fr)
JP (1)	JP7398448B2 (fr)
KR (1)	KR20210084508A (fr)
CN (1)	CN113195475A (fr)
AR (1)	AR116798A1 (fr)
AU (1)	AU2019364739B2 (fr)
BR (1)	BR112021007362A2 (fr)
CA (1)	CA3117289A1 (fr)
CL (1)	CL2021001025A1 (fr)
CO (1)	CO2021004679A2 (fr)
CR (1)	CR20210207A (fr)
DO (1)	DOP2021000062A (fr)
EA (1)	EA202190854A1 (fr)
ES (1)	ES3026145T3 (fr)
IL (1)	IL282240B2 (fr)
MA (1)	MA53973A (fr)
MX (1)	MX2021004593A (fr)
PE (1)	PE20211781A1 (fr)
PH (1)	PH12021550813A1 (fr)
PL (1)	PL3870577T3 (fr)
PT (1)	PT3870577T (fr)
SG (1)	SG11202103560YA (fr)
TW (1)	TWI824041B (fr)
WO (1)	WO2020084492A1 (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2019198024A1 (fr) *	2018-04-11	2019-10-17	VIIV Healthcare UK (No.5) Limited	Composés de 4-oxo-3,4-dihydroquinazoline utilisés en tant qu'inhibiteurs de la réplication du virus de l'immunodéficience humaine
MA53973A (fr) *	2018-10-24	2022-02-09	Viiv Healthcare Uk No 5 Ltd	Inhibiteurs de la réplication du virus de l'immunodéficience humaine
EP3643711A1 (fr)	2018-10-24	2020-04-29	Bayer Animal Health GmbH	Nouveaux composés anthelminthiques
EP3986561B1 (fr) *	2019-06-19	2024-02-14	VIIV Healthcare UK (No.5) Limited	Dérivés de pyrido [2,3-d] pyrimidine en tant qu'inhibiteurs de la réplication du virus de l'immunodéficience humaine
TW202128648A (zh) *	2019-10-04	2021-08-01	英商Ｖｉｉｖ醫療保健英國(Ｎｏ 5)有限公司	人類免疫不全病毒複製之抑制劑
WO2021070054A1 (fr) *	2019-10-08	2021-04-15	VIIV Healthcare UK (No.5) Limited	Inhibiteurs de la réplication du virus de l'immunodéficience humaine
US12564595B2 (en)	2019-11-28	2026-03-03	Shionogi & Co., Ltd.	Prophylactic and therapeutic pharmaceutical agent for HIV infectious diseases characterized by comprising combination of integrase inhibitor and anti-HIV agent
IL293566A (en) *	2019-12-09	2022-08-01	Viiv Healthcare Co	Pharmaceutical preparations containing Cabotgravir
EP4135702B1 (fr) *	2020-04-15	2026-06-03	VIIV Healthcare UK (No.5) Limited	Inhibiteurs de la réplication du virus de l'immunodéficience humaine
AU2022362855B2 (en) *	2021-10-13	2025-08-14	VIIV Healthcare UK (No.5) Limited	Inhibitors of human immunodeficiency virus replication
TW202448483A (zh)	2023-05-31	2024-12-16	美商基利科學股份有限公司	用於ｈｉｖ之治療性化合物
AR132951A1 (es)	2023-06-15	2025-08-13	Viiv Healthcare Uk No 5 Ltd	Métodos e intermedios para preparar compuestos
US20250099464A1 (en)	2023-09-27	2025-03-27	ViiV Healthcare UK (No.3) Limited	Pharmaceutical compositions
AU2023466962A1 (en)	2023-09-27	2026-03-12	ViiV Healthcare UK (No.3) Limited	Pharmaceutical composition of cabotegravir
WO2025169059A1 (fr)	2024-02-05	2025-08-14	VIIV Healthcare UK (No.5) Limited	Inhibiteurs de la réplication du virus de l'immunodéficience humaine

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2005037796A1 (fr)	2003-10-08	2005-04-28	Eli Lilly And Company	Composes et techniques de traitement de la dyslipidemie
CN102464654B (zh)	2010-11-12	2016-01-13	上海泓博智源医药技术有限公司	抗病毒化合物
JP2012201642A (ja) *	2011-03-25	2012-10-22	Tsutomu Takeuchi	１−フェニルピロリジン−２，５−ジオン誘導体を有効成分とするｂａｆｆの結合阻害剤
CA2840095A1 (fr)	2011-07-06	2013-01-10	Gilead Sciences, Inc.	Composes pour traiter le vih
CN102863512B (zh)	2011-07-07	2016-04-20	上海泓博智源医药技术有限公司	抗病毒化合物
US9220710B2 (en)	2013-01-09	2015-12-29	Gilead Sciences, Inc.	Therapeutic compounds
EP2943493B1 (fr)	2013-01-09	2017-08-02	Gilead Sciences, Inc.	Composés thérapeutiques pour le traitement d'infections virales
TW201443037A (zh) *	2013-01-09	2014-11-16	Gilead Sciences Inc	治療用化合物
TWI694071B (zh)	2013-03-01	2020-05-21	美商基利科學股份有限公司	治療反轉錄病毒科(Retroviridae)病毒感染之治療性化合物
WO2015130966A1 (fr)	2014-02-28	2015-09-03	Gilead Sciences, Inc.	Agents antiviraux
WO2015130964A1 (fr)	2014-02-28	2015-09-03	Gilead Sciences, Inc.	Composés thérapeutiques
WO2016033009A1 (fr) *	2014-08-27	2016-03-03	Bristol-Myers Squibb Company	Imidazo [1,2-a] pyridine substitués pour une utilisation en tant qu'inhibiteurs de la réplication du virus de l'immunodéficience humaine
US9873680B2 (en) *	2014-08-29	2018-01-23	Gilead Sciences, Inc.	Therapeutic compounds
LT3347352T (lt)	2016-08-19	2019-08-12	Gilead Sciences, Inc.	Terapiniai junginiai, naudotini živ viruso infekcijos profilaktikai arba terapiniam gydymui
TW201906834A (zh) *	2017-05-02	2019-02-16	英商Viiv醫療保健英國(No.5)有限公司	人類免疫不全病毒複製之抑制劑
WO2019161017A1 (fr)	2018-02-15	2019-08-22	Gilead Sciences, Inc.	Dérivés de pyridine et leur utilisation pour le traitement d'une infection par le vih
KR102847339B1 (ko)	2018-02-16	2025-08-19	길리애드 사이언시즈, 인코포레이티드	레트로비리다에 바이러스 감염의 치료에 유용한 치료 화합물을 제조하기 위한 방법 및 중간체
WO2019198024A1 (fr) *	2018-04-11	2019-10-17	VIIV Healthcare UK (No.5) Limited	Composés de 4-oxo-3,4-dihydroquinazoline utilisés en tant qu'inhibiteurs de la réplication du virus de l'immunodéficience humaine
CA3108633A1 (fr)	2018-08-09	2020-02-13	Viiv Healthcare Uk (No 5) Limited	Inhibiteurs de la replication du virus de l'immunodeficience humaine
JP7361766B2 (ja)	2018-09-14	2023-10-16	ヴィーブヘルスケアユーケー（ナンバー５）リミテッド	ヒト免疫不全ウイルス複製の阻害剤
WO2020058844A1 (fr)	2018-09-20	2020-03-26	VIIV Healthcare UK (No.5) Limited	Inhibiteurs de la réplication du virus de l'immunodéficience humaine
FR3086760A1 (fr)	2018-10-02	2020-04-03	Institut Mines Telecom	Procede d'evaluation de la resistance mecanique d'un echantillon de tissu biologique
WO2020084491A1 (fr)	2018-10-24	2020-04-30	VIIV Healthcare UK (No.5) Limited	Inhibiteurs de la réplication du virus de l'immunodéficience humaine
MA53973A (fr) *	2018-10-24	2022-02-09	Viiv Healthcare Uk No 5 Ltd	Inhibiteurs de la réplication du virus de l'immunodéficience humaine
PT3870575T (pt)	2018-10-25	2023-05-12	Viiv Healthcare Uk No 5 Ltd	Inibidores da replicação do vírus da imunodeficiência humana
ES2969030T3 (es)	2018-10-29	2024-05-16	Viiv Healthcare Uk No 5 Ltd	Derivados de quinazolinil-indazol y su uso como inhibidores de replicación de virus de inmunodeficiencia humana
JP2022506399A (ja)	2018-11-05	2022-01-17	ヴィーブヘルスケアユーケー（ナンバー５）リミテッド	ヒト免疫不全ウイルス複製の阻害剤
US20210395248A1 (en)	2018-11-05	2021-12-23	VIIV Healthcare UK (No.5) Limited	Inhibitors of human immunodeficiency virus replication
UY38559A (es)	2019-02-01	2020-07-31	Viiv Healthcare Uk No 5 Ltd	Inhibidores de la replicación del virus de la inmunodeficiencia humana
US11429555B2 (en)	2019-02-26	2022-08-30	Apple Inc.	Coprocessors with bypass optimization, variable grid architecture, and fused vector operations
EP3749105A4 (fr)	2019-04-11	2021-10-06	Goli Nutrition Inc.	Complément nutritionnel au vinaigre de cidre de pomme
US20220211704A1 (en)	2019-04-30	2022-07-07	Viiv Healthcare Uk (No. 5) Limited	Inhibitors of human immunodeficiency virus replication
EP3986561B1 (fr)	2019-06-19	2024-02-14	VIIV Healthcare UK (No.5) Limited	Dérivés de pyrido [2,3-d] pyrimidine en tant qu'inhibiteurs de la réplication du virus de l'immunodéficience humaine
EP4038068A1 (fr)	2019-10-01	2022-08-10	VIIV Healthcare UK (No.5) Limited	Dérivés de-4-oxo-3,4-dihydropyrido[2,3-d]pyrimidin-2-yle n-substitués utilisés comme inhibiteurs de la réplication du virus de l'immunodéficience humaine
ES2974657T3 (es)	2019-10-01	2024-07-01	Viiv Healthcare Uk No 5 Ltd	Derivados de n-substituido-6-oxo-1,6-dihidropirimidina-2-ilo como inhibidores de la replicación del virus de inmunodeficiencia humana
TW202128648A (zh)	2019-10-04	2021-08-01	英商Ｖｉｉｖ醫療保健英國(Ｎｏ 5)有限公司	人類免疫不全病毒複製之抑制劑
US12703699B2 (en)	2020-03-06	2026-08-11	Viiv Healthcare Uk (No. 5) Limited	Inhibitors of human immunodeficiency virus replication

2019
- 2019-10-22 MA MA053973A patent/MA53973A/fr unknown
- 2019-10-22 PL PL19794683.3T patent/PL3870577T3/pl unknown
- 2019-10-22 CA CA3117289A patent/CA3117289A1/fr active Pending
- 2019-10-22 TW TW108138086A patent/TWI824041B/zh active
- 2019-10-22 ES ES19794683T patent/ES3026145T3/es active Active
- 2019-10-22 AR ARP190103016A patent/AR116798A1/es not_active Application Discontinuation
- 2019-10-22 KR KR1020217015003A patent/KR20210084508A/ko not_active Ceased
- 2019-10-22 CR CR20210207A patent/CR20210207A/es unknown
- 2019-10-22 CN CN201980085915.8A patent/CN113195475A/zh active Pending
- 2019-10-22 WO PCT/IB2019/059020 patent/WO2020084492A1/fr not_active Ceased
- 2019-10-22 JP JP2021522518A patent/JP7398448B2/ja active Active
- 2019-10-22 EP EP19794683.3A patent/EP3870577B1/fr active Active
- 2019-10-22 PE PE2021000571A patent/PE20211781A1/es unknown
- 2019-10-22 PT PT197946833T patent/PT3870577T/pt unknown
- 2019-10-22 EA EA202190854A patent/EA202190854A1/ru unknown
- 2019-10-22 SG SG11202103560YA patent/SG11202103560YA/en unknown
- 2019-10-22 US US16/762,209 patent/US11541055B2/en active Active
- 2019-10-22 IL IL282240A patent/IL282240B2/en unknown
- 2019-10-22 MX MX2021004593A patent/MX2021004593A/es unknown
- 2019-10-22 AU AU2019364739A patent/AU2019364739B2/en not_active Ceased
- 2019-10-22 BR BR112021007362-0A patent/BR112021007362A2/pt unknown
2021
- 2021-04-08 PH PH12021550813A patent/PH12021550813A1/en unknown
- 2021-04-09 DO DO2021000062A patent/DOP2021000062A/es unknown
- 2021-04-14 CO CONC2021/0004679A patent/CO2021004679A2/es unknown
- 2021-04-22 CL CL2021001025A patent/CL2021001025A1/es unknown
2022
- 2022-09-30 US US17/957,569 patent/US20230109662A1/en not_active Abandoned

Also Published As

Publication number	Publication date
IL282240B2 (en)	2025-05-01
KR20210084508A (ko)	2021-07-07
JP2022505841A (ja)	2022-01-14
PT3870577T (pt)	2025-04-07
SG11202103560YA (en)	2021-05-28
US11541055B2 (en)	2023-01-03
PE20211781A1 (es)	2021-09-08
AU2019364739A1 (en)	2021-05-20
CO2021004679A2 (es)	2021-04-30
TWI824041B (zh)	2023-12-01
DOP2021000062A (es)	2021-09-15
WO2020084492A1 (fr)	2020-04-30
CA3117289A1 (fr)	2020-04-30
ES3026145T3 (en)	2025-06-10
TW202031261A (zh)	2020-09-01
IL282240A (en)	2021-05-31
PL3870577T3 (pl)	2025-06-16
US20230109662A1 (en)	2023-04-06
PH12021550813A1 (en)	2021-10-04
CL2021001025A1 (es)	2021-11-05
EP3870577B1 (fr)	2025-03-19
CR20210207A (es)	2021-09-02
BR112021007362A2 (pt)	2021-07-20
EP3870577A1 (fr)	2021-09-01
AU2019364739B2 (en)	2022-05-26
JP7398448B2 (ja)	2023-12-14
US20200360384A1 (en)	2020-11-19
IL282240B1 (en)	2025-01-01
MX2021004593A (es)	2021-06-15
EA202190854A1 (ru)	2021-08-17
CN113195475A (zh)	2021-07-30
AR116798A1 (es)	2021-06-16

Publication	Publication Date	Title
IL282240A (en)	2021-05-31	Inhibitors of human immunodeficiency virus replication
NO2025052I1 (no)	2025-12-04	a combination of (a) vanzacaftor or a pharmaceutically acceptable salt thereof, preferably a calcium salt thereof, (b) tezacaftor or a pharmaceutically acceptable salt thereof, and (c) deutivacaftor or a pharmaceutically acceptable salt thereof
MA44077A (fr)	2021-05-05	Anticorps neutralisants le virus de l'immunodéficience humaine
PT3619205T (pt)	2022-05-03	Inibidores da replicação do vírus da imunodeficiência humana
PT3870575T (pt)	2023-05-12	Inibidores da replicação do vírus da imunodeficiência humana
EP2220046A4 (fr)	2011-01-05	Inhibiteurs de la réplication du virus de l'immunodéficience humaine
EP2220095A4 (fr)	2011-01-26	Inhibiteurs de la réplication du virus de l'immunodéficience humaine
EP2220076A4 (fr)	2011-04-06	Inhibiteurs de la réplication du virus de l'immunodéficience humaine
EP2220084A4 (fr)	2011-01-26	Inhibiteurs de la réplication du virus de l'immunodéficience humaine
CU24498B1 (es)	2021-01-12	Anticuerpos de factor xi
PT3917930T (pt)	2023-03-30	Inibidores da replicação do vírus da imunodeficiência humana
IL285870A (en)	2021-10-31	Leucine, acetyl leucine, and related analogs for treating disease
IL280475A (en)	2021-03-01	A pharmaceutical composition for use in the treatment or prevention of a c5-related disease and a method for treating or preventing a c5-related disease
EP3827837A4 (fr)	2022-05-04	Composition visant à prévenir et traiter des maladies liées au système immunitaire
EP3747459A4 (fr)	2021-12-01	Nouvel immunoadjuvant vaccinal
IL270552A (en)	2020-01-30	Volclospoin composition for treating proteinuric kidney disease
MA42614A (fr)	2021-05-26	Dérivés d'acide 5-(n-benzyl tétrahydroisoquinolin-6-yl) pyridin-3-yl-acétique utilisés comme inhibiteurs de la réplication du virus de l'immunodéficience humaine
EP3811918A4 (fr)	2021-09-01	Fauteuil roulant
EP4038064C0 (fr)	2024-02-21	Dérivés de 6-oxo-1,6-dihydropyrimidine-2-yl n-substitués utilisés en tant qu'inhibiteurs de la réplication du virus de l'immunodéficience humaine
EP3592377A4 (fr)	2021-02-17	Formes posologiques de kallicréine tissulaire 1
IL289371A (en)	2022-02-01	Methylthioninium for use in the treatment of synaptopathies
EP4062884A4 (fr)	2023-10-25	Couche jetable
IL311982A (en)	2024-06-01	Inhibitors of human immunodeficiency virus replication
DK3863580T3 (da)	2022-12-05	Engangsble
EP3773400C0 (fr)	2023-09-13	Fauteuil roulant